CN102512655B - L-carnitine composition, L-carnitine preparation and preparation method and application thereof - Google Patents
L-carnitine composition, L-carnitine preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN102512655B CN102512655B CN2011103915121A CN201110391512A CN102512655B CN 102512655 B CN102512655 B CN 102512655B CN 2011103915121 A CN2011103915121 A CN 2011103915121A CN 201110391512 A CN201110391512 A CN 201110391512A CN 102512655 B CN102512655 B CN 102512655B
- Authority
- CN
- China
- Prior art keywords
- carnitine
- vitamin
- preparation
- parts
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 22
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 21
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 21
- 244000068988 Glycine max Species 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 46
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 46
- 229960003624 creatine Drugs 0.000 claims description 23
- 239000006046 creatine Substances 0.000 claims description 23
- 229960003080 taurine Drugs 0.000 claims description 23
- 235000012661 lycopene Nutrition 0.000 claims description 20
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 18
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 18
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 18
- 229960004999 lycopene Drugs 0.000 claims description 18
- 239000001751 lycopene Substances 0.000 claims description 18
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 229940088594 vitamin Drugs 0.000 claims description 15
- 229930003231 vitamin Natural products 0.000 claims description 15
- 235000013343 vitamin Nutrition 0.000 claims description 15
- 239000011782 vitamin Substances 0.000 claims description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 229930003270 Vitamin B Natural products 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 235000019156 vitamin B Nutrition 0.000 claims description 5
- 239000011720 vitamin B Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 230000001965 increasing effect Effects 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 150000002664 lycopenes Chemical class 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 25
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 230000000386 athletic effect Effects 0.000 abstract 1
- 238000002485 combustion reaction Methods 0.000 abstract 1
- 230000033001 locomotion Effects 0.000 description 24
- 206010016256 fatigue Diseases 0.000 description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 229960000310 isoleucine Drugs 0.000 description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000004474 valine Substances 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229960002743 glutamine Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- -1 hydroxyl isomaltulose Chemical compound 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- BQMPVGMHZKZPBH-BYZBDTJCSA-N (3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O BQMPVGMHZKZPBH-BYZBDTJCSA-N 0.000 description 1
- NRTLIYOWLVMQBO-UHFFFAOYSA-N 5-chloro-1,3-dimethyl-N-(1,1,3-trimethyl-1,3-dihydro-2-benzofuran-4-yl)pyrazole-4-carboxamide Chemical compound C=12C(C)OC(C)(C)C2=CC=CC=1NC(=O)C=1C(C)=NN(C)C=1Cl NRTLIYOWLVMQBO-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229930187479 gypenoside Natural products 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 230000009183 running Effects 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an L-carnitine composition, an L-carnitine preparation and a preparation method and application thereof. The composition can comprise L-carnitine or a salt thereof acceptable pharmaceutically, kreatine, branched-chain amino acid, glutamine and soybean peptide. The composition used for improving tolerance can increase the combustion of fat in a human body, effectively oxidize the fat in the human body and decompose the fat into energy, implements nutrition required by the human body, and improves the athletic ability.
Description
Technical field
The present invention relates to a kind of health food that contains L-carnitine, be specifically related to a kind of L-carnitine compositions and preparation, and its preparation method and application.
Background technology
Exercise fatigue refers to that the physiological process of physical function can not continue can not keep predetermined exercise intensity at specified level and/or integral body.The generation of exercise fatigue is many-sided, as: metabolic waste is piled up, movable desired substance exhaustion etc.During high-intensity exercise, energy requirement is greater than maximum aerobic metabolism power and the high-caliber anaerobic metabolism of needs of individuality.When maximum intensity moves to fatigue, phosphagen (CP) is by a large amount of consumption (reaching reserves 90%), then concentration reduces in muscle, can cause fatigue, the supply energy of the generation of ADP and ATP constantly consumes in the mitochondrion, as ADP again phosphorylation generate ATP speed and slow down, also can cause fatigue.H+ is the important reason of exercise fatigue, and when exercise fatigue, muscle pH can be down to 6.33, and this is to cause tired principal element: 1) suppress the phosphofructokinase activity and reduction sugar decomposition speed; 2) competitive inhibition Ca
2+Reduce the cross-bridges activeness in conjunction with TnC; 3) suppress sarcoplasmic reticulum ATP-ase and reduce Ca
2+Heavily absorb and Ca subsequently
2+Discharge.
Chinese patent application 200510086556.8 (title: a kind of beverage that promotes sportive recovery from fatigue; open day: on April 19th, 2006) provide a kind of beverage that promotes sportive recovery from fatigue; its main component is L-glutaminate, taurine, creatine, vitamin, gypenoside and glucose, can also add trace element and the lactalbumins such as ferrum, zinc.The effects of component aspect resisting fatigue such as glutamine, taurine, creatine, vitamin are namely disclosed; but effect is relatively poor, and the inventor finds through a large amount of research, an amount of increase some or change some compositions after; can more efficientlyly slow down the generation of exercise fatigue, improve exercise tolerance.
Summary of the invention
The purpose of this invention is to provide a kind of L-carnitine compositions, it can accelerate the burning of fat in the health, effectively makes the body fat oxidation Decomposition be converted into energy, replenishes the required nutrition of health, improves motor capacity.
Another object of the present invention is to provide a kind of L-carnitine preparation.
Another purpose of the present invention is to provide the preparation method of described L-carnitine preparation.
A further object of the present invention has been to provide the application in preparation raising endurance medicine of a kind of described L-carnitine compositions or preparation.
The invention provides a kind of L-carnitine compositions, by weight, comprise following raw material: L-carnitine or its pharmaceutically acceptable salt 10-300 part, glutamine 500-1500 part, branched-chain amino acid 300-600 part, soybean peptide 100-300 part and creatine 100-300 part.
Described L-carnitine compositions by weight, preferably comprises following raw material: L-carnitine or its pharmaceutically acceptable salt 25-200 part, glutamine 800-1200 part, branched-chain amino acid 400-500 part, soybean peptide 150-250 part and creatine 150-250 part.
Described L-carnitine compositions by weight, more preferably comprises following raw material: 150 parts of L-carnitine or its pharmaceutically acceptable salts, 900 parts of glutamine, 450 parts of branched-chain amino acid, 180 parts of 200 parts of soybean peptide and creatines.
Described L-carnitine compositions, the raw material that also comprises has: taurine, vitamin substances and lycopene.
Wherein, by weight, described taurine 5-60 part, vitamin substances 5-15 part, lycopene 0.5-2.5 part.Preferred taurine 15-50 part, vitamin substances 8-12 part, lycopene 1-2 part.More preferably taurine is 35 parts, 10 parts of vitamin substances, 1.5 parts of lycopenes.
Wherein, described L-carnitine pharmaceutically acceptable salt is selected from one or more in L-carnitine-L-tartrate, Carnitine Fumarate or the L-carnitine hydrochloride.
Wherein, described vitamin substances is vitamin B1, vitamin B2, vitamin C, vitamin B6 or vitamin E.
Wherein, described branched-chain amino acid is leucine, isoleucine and valine.Its weight ratio is (2.0-2.5): 1: (1.0-1.5), and preferred 2: 1: 1.
A kind of L-carnitine preparation provided by the invention is comprised of described L-carnitine compositions and pharmaceutically acceptable excipient.
Wherein, described pharmaceutically acceptable excipient is selected from one or more in diluent, binding agent, sweeting agent and the lubricant.
Wherein, described diluent is selected from one or more in lactose, mannitol, microcrystalline Cellulose, hydroxyl isomaltulose, Sorbitol, xylitol and the isomaltulose.
Wherein, described binding agent is selected from one or both in ethanol and the hydroxypropyl methylcellulose.
Wherein, described lubricant is selected from one or both in magnesium stearate and the soybean oil.
Wherein, described sweeting agent is selected from a kind of how several in Mel, white sugar and the citric acid.
Wherein, the weight portion of described pharmaceutically acceptable excipient is 10-2000 part, is preferably 10-1000 part, more preferably 300 parts.Excipient also is called adjuvant.
Described L-carnitine preparation can be solid preparation or liquid preparation.
Wherein, described solid preparation can be tablet, capsule or powder.Capsule can be made hard capsule or soft capsule.Described liquid preparation can be drink.
The unit of weight portion of the present invention can be the known unit of weights of field of medicaments such as μ g, mg, g, kg.
The preparation method of described L-carnitine preparation provided by the invention can adopt conventional method in the art to prepare, and also can by following method preparation, comprise the steps:
1) take by weighing each raw material in the described L-carnitine compositions, crushing screening, for subsequent use;
2) taking by weighing described pharmaceutically acceptable excipient, with this excipient and step 1) described each raw material is according to the equivalent method mix homogeneously that progressively increases, and is prepared into various regular dosage forms according to conventional formulation technique.
Compositions of the present invention and preparation have following beneficial effect:
L-carnitine (L-carnitine) claims again VBT, DL-carnitine chloride, and chemical name is beta-hydroxy γ-trimethylamine butanoic acid, is a kind of white crystalline lens or white transparent fine powder.L-carnitine is the moisture absorption very easily, and stable good can place in the solution of pH 3-6 more than 1 year, ability more than 200 ℃ high temperature and have preferably solubization and water absorption.L-carnitine has been applied to the fields such as medicine, health care and food at present.
L-carnitine is that a kind of fat that promotes is converted into the amino acid of energy, and red meat is the main source of L-carnitine, and human body is had no side effect.Dissimilar diets has contained the L-carnitine of 5-100 milligram, but common people can only take in 50 milligrams every day from meals, and vegetarian is taken in still less.The main Physiological Function of L-carnitine is to promote that fat changes into energy.L-carnitine and salt thereof are a kind of special acids that extensively is present in body tissue, it is lipometabolic necessary cofactor, can improve sports emotion and enhancing body vigor, increase muscular endurance and motor capacity, there is positive effect the aspects such as alleviation and resisting fatigue.
Soybean peptide is to adopt modern biological enzymolysis technology, after the soybean protein molecule is separated through enzyme action, and the small molecular protein peptide that obtains.It had both had soy proteinaceous nutritive peculiarity, had again the peculiar good biological activity of small-molecular peptides and physiological function.Supplement the nutrients rapidly, strengthen nutrition, allaying tiredness for the athlete increases muscle quantities, regains one's strength.Soybean peptide is fast in intestinal absorption, has antioxidant activity, can also promote the increase of sport people lean body mass, improves the sport people serum testosterone, reduces the tired grade of sport people, serum creatine kinase level after the motion of reduction sport people, Cell protection film.
Creatine is the natural nutrient that is present in body, and 95% creatine all is present in the skeletal muscle.The resynthesis of the ATP that consumes during the creatine of intramuscular abundance can guarantee to move reduces to greatest extent the generation of the lactic acid of muscle part, thereby people's physical ability is moved the longer time under higher intensity.This just can help human body to gain in strength, increase the acting ability, increase muscle, and makes human body fatigue can not occur too early.Studies show that creatine can increase the ability of muscle fiber panning protein.Actin and myosin all are essential for the contraction of all muscle.When human body by the picked-up creatine, when having promoted that these contractile proteins synthesize, then increased the ability that muscle is engaged in physical exertion, in the shorter time, can finish more work.Therefore creatine is good nutriment for the athlete who improves explosive force, carries out strength building.
Glutamine is in blood and the cell, the highest free amino acid of skeletal muscle intensive amount particularly, and it has consisted of 61% of skeletal muscle free amino acid pond.Recently about studies show that of glutamine and taurine, they can be when human body produces strong metabolic stress (body that causes such as exacting practice and match stress), promotes the anabolism of protein and reduces the decomposition of muscular tissue.Glutamine is the carrier of nitrogen, and has the effect of important cell increase-volume, studies show that, only replenishing glutamine 2-6g every day just has obvious positive interaction to protein metabolism and cell increase-volume.These effects all can promote the growth of the synthetic and cell of myocyte's internal protein.Also have research to find, use the low dose of glutamine can also stimulating immune system, serve as the fuel of immunocyte, correct acidosis, keep the normal pH value of blood.Yet the strength building of large intensity can make glutamine reduce by 50%, and a few hours just can return to original level after the motion.People's immunity after motion is low than usual, and this is that the decline of body glutamine level causes.If there is the problem of hypoimmunity in the athlete, in case they the flu or wound infection, the time of its recovery than under normal circumstances slowly many, this also will hinder finishing of exercise program.This shows that replenishing of glutamine is very important concerning them.
Branched-chain amino acid (leucine, isoleucine, valine) after training, recover with procedure of adaptation in bring into play pivotal role, branched-chain amino acid is the precursor substance that muscular energy produces, and also is simultaneously immune system and activates the fuel that recovers mechanism.Therefore its tired and anti-muscle protein of bioavailability, delay that helps to improve carbohydrate decomposes.
Lycopene (lycopene) is the main pigment of mature tomato, is a kind of oxygen-free carotenoid.In carotenoid, it has the strongest antioxidant activity.The effect that lycopene is removed free radical outclass other carotenoid and vitamin E, and the speed constant of its singlet-oxygen quenching is 100 times of vitamin E, is one of found powerful antioxidant of occurring in nature up to now.
Taurine is a kind of special aminoacid, is the requisite a kind of nutrient of human body, and the effect of balance health is arranged.Scientific research finds that taurine has protective effect to eyes, lung, liver, gastrointestinal etc.In addition; taurine can and generate the avirulence material in conjunction with the hypochlorous acid in the leukocyte; reduce hypochlorous acid to the destruction of leukocyte self; thereby raising body immunity; simultaneously, taurine can be kept cardiac function, makes blood circulation normalization; thereby the allaying tiredness product makes effectively produce power of body., it has the effect that alleviates and prevent myocardial damage after the motion of exhausting property of power, the motor capacity that can improve body after replenishing, it mainly is that generation by opposing body periphery fatigue realizes.
Vitamin B group can promote energy metabolism, alleviates the mental pressure of movement human.Vitamin C and vitamin E can be removed free radical, improve immunologic function, reduce the injury of radical pair body, the generation of delay fatigue.
In a word; L-carnitine compositions provided by the invention makes up L-carnitine or its pharmaceutically acceptable salt, creatine, branched-chain amino acid, glutamine, soybean peptide, can add taurine, vitamin substances and lycopene again; further, carry out in specific proportions composite.Wherein, L-carnitine is the fatty acid oxidation carrier, fat can be transferred to mitochondrion, carries out oxidation Decomposition in mitochondrion, for body provides energy; Other materials provide nutrition for body, thereby can improve the endurance of motion, slow down the generation of exercise fatigue and promote tired recovery.Especially can effectively promote body SOD to raise, strengthen the ability of body free radical resisting.
The specific embodiment
Following examples are used for explanation the present invention, but are not used for limiting the scope of the invention.
Embodiment 1: capsule
1, prescription (weight): L-carnitine-L-tartrate 25g, VITAMIN B15 g, lycopene 1g, creatine 100g, branched-chain amino acid 300g (leucine 150g, isoleucine 75g, valine 75g), glutamine 500g, taurine 5g, soybean peptide 100g, isomaltulose 100g, magnesium stearate 10g.
2, preparation method:
1) take by weighing L-carnitine-L-tartrate, vitamin B1, lycopene, creatine, branched-chain amino acid, glutamine, taurine, soybean peptide according to prescription, cross respectively 40 mesh sieves, for subsequent use;
2) take by weighing isomaltulose and magnesium stearate according to prescription, above-mentioned supplementary material by the equivalent method mix homogeneously that progressively increases, is poured in the capsule-filling mould, fill capsule, polishing, packing.
Embodiment 2: powder
1, prescription (weight): Carnitine Fumarate 300g, vitamin C 15g, lycopene 2.5g, creatine 300g, branched-chain amino acid 600g (leucine 300g, isoleucine 120g, valine 180g), glutamine 1500g, taurine 60g, soybean peptide 300g, hydroxyl isomaltulose 2000g.
2, preparation method:
1) take by weighing L-carnitine-L-tartrate, vitamin C, lycopene, creatine, branched-chain amino acid, glutamine, taurine, soybean peptide according to prescription, cross respectively 40 mesh sieves, for subsequent use;
2) take by weighing hydroxyl isomaltulose according to prescription, with above-mentioned supplementary material by the equivalent method mix homogeneously that progressively increases, packing.
Embodiment 3: tablet
1, prescription (weight): L-carnitine 150g, vitamin B
610g, lycopene 1.5g, creatine 180g, branched-chain amino acid 450g (leucine 125g, isoleucine 90g, valine 135g), glutamine 900g, taurine 35, soybean peptide 200g, microcrystalline Cellulose 700g, lactose 1200g, magnesium stearate 40g.
2, preparation method:
1) take by weighing L-carnitine-L-tartrate, vitamin B6, lycopene, creatine, branched-chain amino acid, glutamine, taurine, soybean peptide according to prescription, cross respectively 40 mesh sieves, for subsequent use;
2) take by weighing microcrystalline Cellulose, lactose, magnesium stearate according to prescription, by the equivalent method mix homogeneously that progressively increases, use 50% ethanol as binding agent above-mentioned supplementary material; soft material processed; with above-mentioned soft material granulation in the oscillating granulator of 14 eye mesh screens, granule is inserted in the multi-functional boiling drier, about 40 minutes of 50 ℃ of airpillow-dry; the control pellet moisture is 5%; then granulate adds magnesium stearate in granule, total mixed; tabletting, packing.
Embodiment 4: capsule
Preparation method is with embodiment 1, and the prescription of different is this capsule is:
L-carnitine-L-tartrate 50g, vitamin B2 8g, lycopene 1.8, creatine 150g, branched-chain amino acid 495g (leucine 275g, isoleucine 110g, valine 110g), glutamine 1000g, taurine 40g, soybean peptide 150g, microcrystalline Cellulose 100g, magnesium stearate 5g.
Embodiment 5: oral liquid
1, prescription (weight): L-carnitine-L-tartrate 12kg, glutamine 50kg, branched-chain amino acid 40kg, soybean peptide 20kg, creatine 15kg, Mel 10kg, white sugar 8kg, citric acid 1kg.
2, preparation method:
1) take by weighing supplementary material, cross respectively 40 mesh sieves, for subsequent use;
2) with above former, adjuvant except Mel according to the equivalent method mix homogeneously that progressively increases, then be dissolved in the 100kg water, add Mel and stir, be sub-packed in the aseptic bottle every bottle of 20ml after the sterilization.
Embodiment 6: powder
Preparation method is with embodiment 2, and the component of different is this powder is:
L-carnitine-L-tartrate 100g, vitamin E 12g, lycopene 1.2g, creatine 120g, branched-chain amino acid 450g (leucine 200g, isoleucine 100g, valine 150g), glutamine 700g, taurine 50g, soybean peptide 120g, microcrystalline Cellulose 100g, magnesium stearate 5g.
Embodiment 7: tablet
1, prescription (weight): L-carnitine 60g, vitamin B2 18g, lycopene 1.8g, creatine 100g, branched-chain amino acid 380 (leucine 190g, isoleucine 95g, valine 95g)) g, glutamine 1200g, taurine 45g, soybean peptide 250g; microcrystalline Cellulose 500g, magnesium stearate 10g, lactose 200g.
2, preparation method:
1) take by weighing supplementary material, cross respectively 40 mesh sieves, for subsequent use;
2) take by weighing microcrystalline Cellulose, magnesium stearate and lactose according to prescription, by the equivalent method mix homogeneously that progressively increases, use 50% ethanol as binding agent above-mentioned supplementary material; soft material processed with above-mentioned soft material granulation in the oscillating granulator of 14 eye mesh screens, is inserted granule in the multi-functional boiling drier; about 40 minutes of 50 ℃ of airpillow-dry; the control pellet moisture is 5%, and then granulate adds magnesium stearate in granule; total mixed; tabletting, packing, and get final product.
Experimental example: human experimentation
1 experimental subject and method
1 experimental subject and method
1.1 experimental subject
Take 91 man's long-distance runnings of certain sport university to athlete's (21.8 ± 0.75 years old mean age) as object of study.
1.2 experiment grouping
Grouping: 91 experimenters are divided into 7 groups at random, and blank group (N=13) is taken placebo, 4/day; Experimental group 1-5 takes respectively the prepared sample of embodiment 1-5, and contrast groups is taken the product that embodiment 6 makes in the patent 200510086556.8,2 bags/day, all takes continuously for 8 weeks.Whole experimental session, and prohibit food and the medicine that takes other raising endurance.
1.3 experimental technique
Venous blood when requiring the experimenter before test, to come laboratory on an empty stomach to get peace and quiet, carry out sports load (moving at the Monark energy meter) before the motion, the limber up 1min of elder generation (0 load), then begin with 50W power, increasing load progressively, reach 70%Hrmax (being drawn by trial test mensuration) about 3 minutes, after this namely no longer increase loading, continue 60 minutes to pedal.Centre of motion rate adopts the monitoring of Polar table.Temperature and the humidity of control laboratory.The experimenter tests after taking 8 all nutriments again.
1.4 index and method
Test index: get ear blood 1 per half an hour in the motion, surveys lactic acid.Measurement in the 3rd, 9,15 minute recovers heart rate, gets ear blood survey lactic acid after immediate postexercise, the motion.Second day extracting vein blood in early morning is measured serum superoxide dismutases (SOD) vigor.
Method of testing: blood lactic acid adopts YSI 1500SPORT LACTATE ANALYZER to measure, and method is Enzyme Electrode; Serum superoxide dismutases (SOD) vigor adopts xanthine oxidase to measure, and determining instrument is 721 type spectrophotometers.
1.5 result's statistics
Date processing adopts SPSS10.0 software, and all data represent with means standard deviation, adopt variance and the pairing T method of inspection.
2 experimental results
2.1 the comparison of blood lactate concentration
Table 1: blood lactate concentration (unit: mmoL/L)
| Grouping | Quiet | Immediate postexercise | 3min after motion finishes | 9min after motion finishes | 15min after motion finishes |
| Blank group | 1.60±0.46 | 3.22±0.42 | 3.23±0.53 | 2.21±0.52 | 1.61±0.43 |
| Contrast groups | 1.59±0.45 | 2.92±0.46 | 2.66±0.54 @ | 2.01±0.53 | 1.58±0.47 |
| Experimental group 1 | 1.58±0.43 | 2.74±0.43 | 1.59±0.58 ** | 1.41±0.50 ** | 1.46±0.53 |
| Experimental group 2 | 1.61±0.51 | 2.78±0.40 | 1.62±0.54 ** | 1.39±0.48 ** | 1.38±0.49 |
| Experimental group 3 | 1.57±0.32 | 2.65±0.46 | 1.53±0.59 ** | 1.35±0.45 ** | 1.32±0.58 |
| Experimental group 4 | 1.58±0.34 | 2.70±0.42 | 1.58±0.56 ** | 1.34±0.44 ** | 1.35±0.53 |
| Experimental group 5 | 1.59±0.23 | 2.80±0.41 | 1.68±0.49 ** | 1.51±0.49 ** | 1.45±0.48 |
*The expression experimental group is compared p＜0.01 with the blank group;
@The expression contrast groups is compared p＜0.05 with the blank group.
The result finds out from table 1:
Immediate postexercise, the blood lactate concentration of each experimental group slightly reduces, but does not produce significant difference;
3min after motion finishes, the blood lactate concentration of each experimental group is compared with the blank group, has utmost point significant difference (P＜0.01); Contrast groups is compared with the blank group, has significant difference (P＜0.05);
9min after motion finishes, the level the when blood lactate concentration of each experimental group returns to peace and quiet;
15min after motion finishes, the level when contrast groups and blank group just return to peace and quiet.
Lactic acid is the product that the metabolism of energy substance decomposition obtains in the body in the motor process, and a large amount of acidic materials accumulation cause muscle, joint acid is swollen and spirit is tired.Take the experimental group sample, help to accelerate the removing speed of blood lactic acid in the body, be conducive to prolong exercise tolerance, improve motor capacity.
2.2 motion finishes to recover in rear 3 minutes the comparison of heart rate
The heart rate of 3min test subject the results are shown in Table 2 after immediate postexercise and the motion.
Table 2: motion finishes the rear 3 minutes hearts rate that recover (inferior/as to divide)
| Grouping | At once heart rate (inferior/minute) after motion finishes | Motion finishes the rear 3 minutes hearts rate that recover (inferior/as to divide) |
| Blank group | 140.12±8.48 | 129.23±5.68 |
| Contrast groups | 141.15±6.49 | 119.28±5.73 & |
| Experimental group 1 | 138.45±6.99 | 107.54±6.23 ** |
| Experimental group 2 | 139.15±6.67 | 108.13±6.53 ** |
| Experimental group 3 | 142.32±7.12 | 106.57±6.74 ** |
| Experimental group 4 | 140.68±8.53 | 108.66±6.83 ** |
| Experimental group 5 | 141.35±7.26 | 110.64±7.12 ** |
*The expression experimental group is compared p＜0.01 ， ﹠amp with the blank group; The expression contrast groups is compared p＜0.05 with the blank group.
As can be seen from Table 2:
Motion finishes rear 3 minutes, and the recovery of each experimental group heart rate is compared with the blank group, highly significant (P＜0.01);
Contrast groups is compared with the blank group, and heart rate recovers significantly (P＜0.05).
The heart rate resume speed is fast, shows that experimental group experimenter exercise tolerance is good, and motor capacity is strong.Therefore can find out that experimental group experimenter's resisting fatigue effect is better than blank group and contrast groups.
2.3 oxidation resistance test result
M seq is measured respectively serum superoxide dismutases (SOD) vigor of blank group, contrast groups and each experimental group after the experiment, and experimental result sees Table 3.
Table 3: the rear impact on 4 groups of experimenter's oxidation resistances of experiment
Compare ※ p＜0.05 with the blank group.
As shown in Table 3, the SOD vigor in five groups of experimenter mornings next day is all high than morning on the previous day, all is significantly higher than the previous day (P＜0.05).And contrast groups is compared with the blank group, does not have significant difference.
Show that present patent application obtains compositions and can effectively promote body SOD to raise, and has strengthened the ability of body free radical resisting.
Discuss: motion causes that the body free radical increases, and too much free radical can cause some important metabolic enzymes because of the cross-linked polymeric inactivation, causes a series of pathological change, causes the ability to work of human body to descend and the generation feeling of fatigue.Therefore, accelerate the removing speed of free radical, improve the anti-oxidative defense function, help to improve motor capacity, promote fatigue recovery, reduce peroxidation to the damage of body.
3, conclusion
From whole experimentation, the compositions of resisting fatigue provided by the invention has the effect of Synergistic, and experimenter's blood lactic acid resume speed is accelerated, and it is also fast that heart rate recovers, this all is the key factor that is conducive to prolong exercise tolerance, is conducive to the raising of motor capacity.Motion can cause that the body free radical increases, and too much free radical can cause some important metabolic enzymes because of the cross-linked polymeric inactivation, causes a series of pathological change, causes the ability to work of human body to descend and generation fatigue.Therefore, accelerate the removing speed of free radical, improve the anti-oxidative defense function, significant to improving motor capacity.The antioxidation result of this experiment shows, takes the preparation that said composition makes and can effectively promote body SOD to raise, and can effectively improve the ability of body free radical resisting, to improving motor capacity and promoting that fatigue recovery also has certain effect.
Although, above used general explanation, the specific embodiment and test, the present invention is described in detail, on basis of the present invention, can make some modifications or improvements it, and this will be apparent to those skilled in the art.Therefore, these modifications or improvements all belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (8)
1. L-carnitine compositions, it is characterized in that, by weight, comprise following raw material: L-carnitine or its pharmaceutically acceptable salt 10-300 part, glutamine 500-1500 part, branched-chain amino acid 300-600 part, soybean peptide 100-300 part, creatine 100-300 part, taurine 5-60 part, vitamin substances 5-15 part and lycopene 0.5-2.5 part;
Described vitamin substances is vitamin B
1, vitamin B
2, vitamin C, vitamin B
6Or vitamin E.
2. L-carnitine compositions according to claim 1, it is characterized in that, by weight, comprise following raw material: L-carnitine or its pharmaceutically acceptable salt 25-200 part, glutamine 800-1200 part, branched-chain amino acid 400-500 part, soybean peptide 150-250 part, creatine 150-250 part, taurine 15-50 part, vitamin substances 8-12 part and lycopene 1-2 part;
Described vitamin substances is vitamin B
1, vitamin B
2, vitamin C, vitamin B
6Or vitamin E.
3. L-carnitine compositions according to claim 1, it is characterized in that, by weight, comprise following raw material: 150 parts of L-carnitine or its pharmaceutically acceptable salts, 900 parts of glutamine, 450 parts of branched-chain amino acid, 200 parts of soybean peptide, 180 parts of creatines, 35 parts of taurines, 1.5 parts of 10 parts of vitamin substances and lycopenes;
Described vitamin substances is vitamin B
1, vitamin B
2, vitamin C, vitamin B
6Or vitamin E.
4. the described L-carnitine compositions of any one is characterized in that according to claim 1-3, and described L-carnitine pharmaceutically acceptable salt is selected from one or more in L-carnitine-L-tartrate, Carnitine Fumarate or the L-carnitine hydrochloride.
5. a L-carnitine preparation is characterized in that, is comprised of the described L-carnitine compositions of claim 1-4 any one and pharmaceutically acceptable excipient.
6. L-carnitine preparation according to claim 5 is characterized in that, described preparation is selected from solid preparation or liquid preparation; Described solid preparation is selected from tablet, capsule or powder; Described liquid preparation is selected from drink.
7. a method for preparing claim 5 or 6 described L-carnitine preparations is characterized in that, comprises the steps:
1) take by weighing each raw material in the described L-carnitine compositions, crushing screening, for subsequent use;
2) take by weighing described pharmaceutically acceptable excipient, this excipient and described each raw material of step 1) are progressively increased behind the method mix homogeneously according to equivalent, prepare described L-carnitine preparation.
8. the described L-carnitine compositions of claim 1-4 any one or claim 5 or 6 described L-carnitine preparations are used in preparation raising endurance medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103915121A CN102512655B (en) | 2011-11-30 | 2011-11-30 | L-carnitine composition, L-carnitine preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103915121A CN102512655B (en) | 2011-11-30 | 2011-11-30 | L-carnitine composition, L-carnitine preparation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102512655A CN102512655A (en) | 2012-06-27 |
| CN102512655B true CN102512655B (en) | 2013-10-30 |
Family
ID=46283907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103915121A Active CN102512655B (en) | 2011-11-30 | 2011-11-30 | L-carnitine composition, L-carnitine preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102512655B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110114B (en) * | 2011-11-16 | 2014-05-28 | 北京康比特体育科技股份有限公司 | Beta-alanine-containing composition for endurance increase, and preparation thereof |
| CN104509919A (en) * | 2013-09-30 | 2015-04-15 | 张自力 | Functional nutrient beverage |
| CN104585763A (en) * | 2015-01-28 | 2015-05-06 | 广西博科药业有限公司 | Liver-protecting and liver-nourishing functional food and preparation method thereof |
| CN106620667A (en) * | 2016-12-15 | 2017-05-10 | 钦州市钦南区科学技术情报研究所 | L-carnitine compound having effects of losing weight and reducing grease and preparation method thereof |
| CN106617086A (en) * | 2016-12-30 | 2017-05-10 | 贝克尔（天津）药业有限公司 | Nutritional food capable of enhancing exercise capacity and exercise tolerance |
| CN108283314A (en) * | 2017-11-30 | 2018-07-17 | 新疆阜丰生物科技有限公司 | One kind containing L-Glutamine and three branched-chain amino acid compound health products and preparation method thereof |
| SG11202012984YA (en) * | 2019-06-25 | 2021-01-28 | Metabolic Technologies Inc | STABILITY OF VITAMIN D IN ß-HYDROXY- ß-METHYLBUTYRATE (HMB) |
| CN110801018A (en) * | 2019-11-08 | 2020-02-18 | 广东医科大学 | Coenzyme Q10Vitamin C sports buccal tablet |
| CN111228468A (en) * | 2020-01-14 | 2020-06-05 | 浙江赛沛力运动科技有限公司 | Liquid preparation with effects of improving exercise endurance and helping exercise recovery |
| CN116076740B (en) * | 2023-03-13 | 2024-07-16 | 湖南她练生物科技有限公司 | Stirring device for preparing L-carnitine preparation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1291127B1 (en) * | 1997-04-01 | 1998-12-29 | Sigma Tau Ind Farmaceuti | FOOD SUPPLEMENT FOR SUBJECTS DEDICATED TO INTENSE AND PROLONGED PHYSICAL ACTIVITY |
| CN100356876C (en) * | 2005-09-30 | 2007-12-26 | 北京康比特威创体育新技术发展有限公司 | Beverage for promoting sportive recovery from fatigue |
| CN101390639A (en) * | 2007-09-20 | 2009-03-25 | 中国食品发酵工业研究院 | Anti-fatigue solid beverage containing soya peptide |
-
2011
- 2011-11-30 CN CN2011103915121A patent/CN102512655B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102512655A (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102512655B (en) | L-carnitine composition, L-carnitine preparation and preparation method and application thereof | |
| CN103783532B (en) | A kind of composite protein powder of anti-sarcopenia decay and preparation method thereof | |
| CN100502692C (en) | Physical recovery healthy food and preparation process thereof | |
| CN108651998A (en) | It is a kind of have relieve fatigue PURE WHEY of function and preparation method thereof | |
| CN108618129A (en) | Sarcopenia tailored version clinical nutrition formula and preparation method thereof | |
| CN1364430A (en) | Method for storaging acid liquid or semiliquid composition containing kreatin for human consumption | |
| CN106889412A (en) | One kind is refreshed oneself anti-fatigue solid beverage | |
| CN103750143A (en) | Anti-hypoxia and anti-fatigue energy composition and application thereof | |
| CN101569412B (en) | Sports nutrition supplement and application thereof | |
| CN1321589C (en) | Soy-bean peptide | |
| CN109757733A (en) | A kind of oral polypeptide powder and its preparation method and application | |
| CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
| CN102048884B (en) | Weight-losing composition containing guarana extract | |
| CN108606269B (en) | Sports nutritional supplement and preparation method thereof | |
| CN103704711B (en) | Granules with anti-fatigue and health-care function | |
| CN105919094A (en) | Immunity improving and fatigue preventing composition and preparation method thereof | |
| CN103005435B (en) | Anti-fatigue composition capable of improving speed endurance and preparation containing anti-fatigue composition | |
| CN101214052B (en) | Health food with physical energy fatigue alleviating and immunity reinforcing function | |
| CN101574145B (en) | Nutritional reinforced supplement | |
| CN114786502A (en) | Muscle-building agent | |
| RU2390271C1 (en) | Preparation for increasing of organism adaptability to extreme conditions | |
| CN103110114B (en) | Beta-alanine-containing composition for endurance increase, and preparation thereof | |
| CN107998370B (en) | Composition capable of enhancing body motion ability and relieving motion fatigue | |
| CN107325163B (en) | Astragalus seed protein and its application in anti-exercise fatigue functional food | |
| CN109170913A (en) | A kind of health composition of peptide containing bird's nest, soybean peptide and bone glue of yak former peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wei Bing Inventor after: Li Qigeng Inventor after: Bai Houzeng Inventor after: Jiao Ying Inventor after: Yang Zeyi Inventor after: Zhu Lianjun Inventor after: Liu Yuhua Inventor before: Bai Houzeng Inventor before: Jiao Ying Inventor before: Yang Zeyi Inventor before: Zhu Lianjun Inventor before: Liu Yuhua |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230609 Address after: 102200 No. 5, Lixiang Road, Science Park, Changping District, Beijing Patentee after: BEIJING COMPETITOR SPORTS SCIENCE & TECHNOLOGY Co.,Ltd. Patentee after: Gu'an kangbit Sports Technology Co.,Ltd. Address before: No. 5, Lixiang Road, Science Park, Changping District, Beijing 100069 Patentee before: BEIJING COMPETITOR SPORTS SCIENCE & TECHNOLOGY Co.,Ltd. |